Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus AFEDITAB CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus AFEDITAB CR.
ADALAT vs AFEDITAB CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker